Clinical Trial Update: The Role of OmniLenz® in the Treatment of Small Corneal Perforations Secondary to Exposure Keratitis in ICU Patients [Phase 2, Phase 3]

View source ↗

Summary

The document notes completion of Phase 2 and Phase 3 trials evaluating OmniLenz® for small corneal perforations due to exposure keratitis in ICU patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Perforation
• Exposure Keratitis
• Infectious Keratitis

Drugs mentioned

• OmniLenz®

Snippet

Sponsor: Farwaniya Hospital | Conditions: Corneal Perforation, Exposure Keratitis | Phase 2, Phase 3 | Status: COMPLETED